ClinicalTrials.gg

Program

KAT6A/B Inhibitor BG-75202

Its studies are mostly in Breast Neoplasms, led by BeOne Medicines.

Furthest: phase 1, since Oct 28, 20252 company-led studies, 2 open or runningNext primary completion: Sep 30, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines22 open or runningphase 1since Oct 28, 2025Oct 28, 2025Sep 30, 2028phase 1 · NCT07619287

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 28, 2025First study: phase 1 study in Breast NeoplasmsFirst studyNCT07222267 · 186 planned · United States, Australia, China and more
  2. May 22, 2026Phase 1 study in Myeloid MalignancyNCT07619287 · 118 planned · Australia, China, New Zealand

Ahead

  1. Sep 30, 2028Primary completion: phase 1 study in Myeloid MalignancyNCT07619287
  2. Sep 30, 2029Primary completion: phase 1 study in Breast NeoplasmsNCT07222267

TargetBeta

KAT6A →KAT6B →read by rule
“An orally bioavailable inhibitor of histone acetyltransferases KAT6A (MOZ; MYST3) and KAT6B (MORF; MOZ2; MYST4), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
prifetrastatPfizerphase 310
HRS-2189Jiangsu HengRui Medicinephase 12
KAT6 Inhibitor OP-3136ruleolema-pharmaceuticals-incphase 11
KAT6/KAT7 Inhibitor PF-08032562rulePfizerphase 11
KAT6/KAT7 Inhibitor IDE574ruleideaya-biosciencesphase 11
HLX97Fosun Pharmaphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07619287Myeloid Malignancy · Australia, China, New Zealand1RecruitingSep 30, 2028118
NCT07222267Breast Neoplasms · United States, Australia, China and more1RecruitingSep 30, 2029186

How it is read

Names in the registry

  • “BG-75202”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.